Antacid Market by Forecast to 2025 with Leading Key Players: GlaxoSmithKline plc; Bayer AG; Boehringer Ingelheim International GmbH and Others

The global Antacid Market size is expected to reach USD 7.91 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 3.9% over the forecast period. The trend of self-medication for occasional heartburn is one of the major factors driving the market.

Growing geriatric population is expected to positively impact the overall market for antacid. According to the United Nations Department of Economic And Social Affairs (DESA), the global elderly population (60 years and above), was around 962 million in 2017. This number is expected to grow at the fastest rate in Latin America with 71% increase in population aged 60 and over, followed by Asia with 66%, Africa with 64%, North America with 41%, and Europe with 23%.

Key players operating in antacid market focus on product enhancement to cater to patient requirements, such as changing the dosage form into chewable tablets, powder, and jelly. Also, these players are involved in collaborations and acquisitions to expand their market presence. For instance, in 2017, Pfizer, Inc. entered into a strategic agreement with AstraZeneca to acquire one of the antacid brands, Neksium for a value of INR 75 crores in India to boost its product portfolio.

The easy availability of antacids over-the-counter offer growth opportunities for the sales of overall market. Some of the key players areGlaxoSmithKline plc; AstraZeneca; Pfizer, Inc.; Sun Pharmaceuticals Industries Ltd.; Dr. Reddy’s Laboratories Ltd.; Bayer AG; Takeda Pharmaceutical Company Limited.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/antacids-market

Further key findings from the report suggest:

• In 2017, tablet segment led the antacid market due to high efficacy compared to other dosage forms. Liquid is anticipated to be the fastest growing segment due to its palatable taste and preferred choice for children and elderly population
• Retail pharmacy led the distribution channel segment due its accessibility and availability. Online pharmacy is anticipated to be the fastest growing segment due to growing adoption of Pharma 3.0 and consumer awareness
• Asia Pacific is estimated to be the largest and fastest growing region over the forecast period due to presence of key players such as GlaxoSmithKline plc; Pfizer Inc.; and Abbott among others
• North America held the second largest market share in 2017 owing to increasing prevalence of different digestive disorders
• Some of the key companies operating in this market are GlaxoSmithKline plc; Bayer AG; Boehringer Ingelheim International GmbH; Dr. Reddy’s Laboratories Ltd.; Reckitt Benckiser Group plc; Sun Pharmaceuticals Ltd.; Sanofi; Takeda Pharmaceutical Company Limited; Pfizer Inc.; and Procter & Gamble.

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Antibody Drug Conjugate Market: Industry Analysis and Outlook Report, 2025

The global Antibody Drug Conjugate Market size is expected to reach USD 9.93 billion by 2025, according to a new report by Grand View Research, Inc. it is projected to expand at a CAGR of 25.9% over the forecast period. Increasing incidence of cancer coupled with growing geriatric population are likely to drive the market for Antibody-Drug Conjugates (ADC). Furthermore, major technological advancements are also contributing to drive the growth. According to the World Health Organization (WHO), the number of people aged 65 years and above, is projected to reach 16% of the total population by 2050 from 7% in 2000. Aging has become a substantial risk factor for numerous diseases including cancer and others. Hence, the growing geriatric population is expected to drive growth of the market over the forecast period.

Until 2018, four ADCs were available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due to appropriate targeting and improved technology, ADCs have been gaining a lot of attention from both small and large pharmaceutical companies. Currently there are more than 50 ADCs in clinical trials and it has been projected that during the forecast period three to four ADCs will be commercialized in the area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma.

Seattle Genetics and Roche are leading the antibody drug conjugate market in terms of market share. Until 2017 only two ADCs were commercially available-Adcetris by Seattle Genetics and Kadcyla by Roche. Recently, two more Pfizer’s products were approved to be marketed for acute myeloid leukaemia and acute lymphoblastic leukaemia. Hence, it has been estimated that over the forecast period, Pfizer is anticipated to gain a significant market share.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market

Further key findings from the report suggest:

• Breast cancer was the largest segment in 2017 and is likely to witness a significant growth over the forecast period due to the factors such as availability of Kadcyla and high prevalence of breast cancer
• Cleavable linker is expected to witness the fastest growth over the forecast period as the maximum product in the pipeline contains cleavable linkers. In addition, in 2017 two new products-Besponsa and Mylotarg were approved in the market
• In 2017, North America was the largest revenue generating region in the antibody-drug conjugates market. It is the most well-established regions in terms of patient awareness and usage of ADCs and makes up most of the existing market
• The players operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
• Market players are adopting strategies, such as introducing technologically advanced products, collaborations, and geographic expansions to increase their market share. For instance, Seattle Genetics collaborated with Takeda for developing brentuximab vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Hand-held Surgical Instruments Market by Forecast to 2025 with Leading Key Players: B. Braun Melsungen AG, Integra LifeSciences Corporation and Others

The global Hand-Held Surgical Instruments Market size is expected to reach USD 6.51 billion by 2025 at a 7.1% CAGR during the forecast period, according to a new report by Grand View Research, Inc. The market is anticipated to be driven by rise in number of surgical procedures being performed and increase in prevalence of chronic diseases. In addition, rise in number of road and other accidents globally is contributing to high demand for these surgical instruments.

According to data revealed by the Center for Disease Control and Prevention (CDC) in 2017, 15% of the U.S. population suffers from chronic kidney disease. Hence, with rising prevalence of chronic diseases, need for surgical treatment has been increasing. This is, in turn, accelerating demand for handheld surgical instruments. As per WHO, around 10 million people are injured or disabled due to road accidents every year, which has also resulted in growing number of wound surgeries. This is expected to positively impact market growth in the long run.

In addition, as per Plastic Surgery Statistics Report released by the American Society of Plastic Surgeons, in U.S., around 17.5 million cosmetic surgeries and minimally invasive procedures were performed in 2017. This showcases that the number of surgeries being performed is expected to rise in future.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/hand-held-surgical-instruments-market

Further key findings from the study suggest:

• By product, the others segment dominated the market in 2017 owing to high adoption of various types of surgical tools such as clamps, cannulas, closure devices, bone rasps, needle holders, dissectors, suction tubes, and other cutting instruments
• Rise in general surgeries, wound injuries, and urologic surgeries, such as prostate cancer surgery and urinary obstruction surgery, has led to high revenue generation of the others segment by application
• Plastic and reconstructive surgery is expected to witness the fastest growth over the forecast period due to rise in number of cosmetic surgical procedures such as liposuction, breast augmentation, and abdominoplasty
• On the basis of end use, the hospitals segment is fueled by presence of well-equipped operating rooms
• Clinics held a significant revenue share in 2017 owing to rise in number of dental and other specialized clinics throughout the world, resulting in increased demand for handheld surgical tools
• North America dominated the market in 2017 due to presence of well-developed healthcare infrastructure and leading market players in the region; Asia Pacific is projected to showcase the highest growth during the forecast period owing to rising prevalence of chronic diseases, burn cases, and high child birth rate
• Some of the key companies are B. Braun Melsungen AG, Integra LifeSciences Corporation, Smith & Nephew, Medtronic, Zimmer Biomet Holdings, Becton, Dickinson and Company, and Johnson & Johnson.

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Microfluidics Prototype Market: Industry Analysis and Outlook Report, 2025

The global Microfluidics Prototype Market size is expected to reach USD 1.8 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 20.54% over the forecast period.Introduction of advanced technologies, increasing demand for low volume sample analysis, and emergence of 3D printing technology are among the key factors likely to drive the market during the forecast period.

The microfluidics prototype market is anticipated to witness high growth in the forthcoming years due to increasing investment by key market players to expedite technological innovations in the developing industry. In July 2018, TechX Pioneer Program of the Oil and Gas Technology Center, awarded RAB Microfluidics with a 12-month fellowship platform including business development training, mentorship from business consultants, and funding aid. The grant was made for the development of a miniature lab-on-chip technology for rotating equipment offering predictive failure analysis and real-time condition monitoring.

The development of microfluidics devices involves a high operational cost due to functions, such as microfabrication. Moreover, most of the prototyping methods for microfluidics devices are not compatible with batch process. The scale-up of this method is a costly and complicated affair. This has led to an emphasis on the development of cheaper systems. For instance, in March 2018, researchers from the National University of Singapore (NUS) developed a microfluidic chip that can detect nano-bioparticles without the use of fluorescent labels providing disease diagnosis at a low cost.

Rising research and development activities are anticipated to bode well for market growth in Asia Pacific. For instance, in India, the Microfluidics and Biological Physics Group of Indian Institute of Technology Bombay uses microfluidics technology to build point-of-care diagnostic platforms. The team uses conventional microfluidic devices and different alternate substrates to design and develop affordable lab-on-chip platforms.

The global market for microfluidics prototype is startup-driven and is highly supported by government and private institutions. For instance, in October 2017, the National Institute of Health, USA, awarded Neofluidics with a Phase 1 Small Business Innovation Research (SBIR) grant of USD 175,000. The grant was allotted to develop a microfluidic device for drug screening and disease modeling studies using zebrafish embryos.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/microfluidics-prototype-market

Further key findings from the report suggest:

• Introduction of advanced technologies, increasing demand for low volume sample analysis, and emergence of 3D printing technologyare expected to propel the market at a CAGR of 20.54% from 2018 to 2025
• North America held the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to the presence of more than 170 service providers, abundant funding opportunities, and R&D investments
• Asia Pacific region is anticipated to spearhead the market in terms of growth rate over the forecast period. Presence of university research groups and spinoffs contribute significantly to the growth.
• Key contributors in microfluidics prototype market are microLIQUID; thinXXS Microtechnology; Potomac; uFluidix; Alvéole; Micronics, Inc.; ALine, Inc.; and research groups from various universities.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Hair Removal Devices Market by Forecast to 2025 with Leading Key Players: Cynosure Inc.; Solta Medical, Inc.; Lumenis; Alma Lasers and Others

The global Hair Removal Devices Market size is expected to reach USD 3.4 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 14.9% over the forecast period. Growth in beauty consciousness particularly among women has boosted the market. The male population is also following this trend due to rise in awareness about grooming. This factor is projected to further fuel the demand.

High demand for noninvasive techniques for hair removal such as the laser treatment owing to its benefits, such as precision and saving time and money in the long run. Most hair removal devices can be used at home, which, in turn, is also contributing to the high demand for personal noninvasive grooming techniques.

Availability of technologically advanced products has also played an important role in positively impacting the growth of the market. New laser devices emit longer wavelengths of light, enabling them to focus only on the melanin present in hair follicles. This eliminates the risk of skin burns. These factors are expected to drive growth of the hair removal devices market over the years to come.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/hair-removal-devices-market

Further key findings from the study suggest:

• Laser devices held the largest share of the hair removal devices market in 2017 owing to benefits such as painless treatment and rapid hair reduction
• Diode lasers is a lucrative segment as these devices provide rapid hair reduction with minimum adverse effects
• IPL systems also held a high market share in 2017 as these devices are more affordable than other devices
• In 2017, beauty clinics dominated the market because a large number of women prefer rapid treatment sessions unlike dermatology clinics
• Home use segment is anticipated to exhibit impressive growth over the forecast period due to easy availability of these devices through retail and online distribution channels
• North America held the largest market share in 2017 due to well-developed healthcare infrastructure and growth in the number of hair reduction procedures in U.S.
• Asia Pacific is anticipated to witness highest growth over the forecast period owing to increasing awareness about advanced equipment and availability of affordable laser hair removal devices in China
• Some of the key market players include Cynosure Inc.; Solta Medical, Inc.; Lumenis; Alma Lasers; Syneron Medical Ltd.; Venus Concept Canada Corp.; and Cutera. 

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Europe Blood Screening Market Analysis Report by Product and technology, 2025

The Europe Blood Screening Market size is expected to reach USD 1.17 billion by 2025 according to a new report by Grand View Research, Inc. The market is expected to record a CAGR of 7.7% during the forecast period. Increasing number of blood transfusion processes performed along with stringent regulations in Europe mandating screening tests, such as NAT for testing HIV, HBV, and HCV, is contributing to the market growth.

Moreover, growth in the overall number of complex surgeries that require a large amount of blood and blood products along with rising cases of road accidents is expected to drive the market further. Additionally, import of products through contract agreements and development in the product technology by manufacturers of blood screening reagents and instruments are contributing to market expansion in the region.

For example, DiaSystem Scandinavia AB signed a distribution agreement with SNIBE, an Asian immunology test producer that focuses on immunoassay analyzers based on CLIA technology. DiaSystem specializes in the production and supply of reagents used in chemistry and immunoturbidimetry. This agreement has provided the former company with automated chemiluminescence instrument delivering a complete analytical system in areas, such as thyroid, renal function, hepatitis, and hepatic fibrosis.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/europe-blood-screening-market/

Further key findings from the study suggest:

• NAT led the technology segment in 2017 owing to a regulatory obligation for mandatory NAT screening for all blood donations.
• On the basis of product, reagents led the Europe blood screening market in 2017
• Germany held a majority of the market share in 2017 due to large number of blood donors.
• Moreover, stringent regulations in the country for screening of donations also contributed to its growth. The Paul-Ehrlich-Institut, a medical regulatory body in Germany, mandates NAT testing for HCV and HIV for all blood donations.
• Roche Diagnostics; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Grifols, S.A.; Becton, Dickinson and Company; Agilent Technologies; Thermo Fisher Scientific, Inc.; and Danaher Corp. are some of the key companies operating in this market.

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

U.S. Urgent Care Market Analysis, Scope, Growth Opportunities and Forecast Report till 2025

The U.S. Urgent Care Market size is expected to reach USD 30.6 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a 6.2% CAGR during the forecast period. Increase in incidence of chronic diseases, rising affordability of emergency care, and growing demand for cost-effective treatment for geriatric population are factors likely to drive the market during the forecast period.

The U.S. urgent care market is expected to witness high growth in the coming years due to increasing investments by service providers and growing recognition and need to provide affordable care. In addition, growing medical coverage is anticipated to propel market growth. According to the Patient Protection and Affordable Care (PPAC) Act, 2010, approximately 32 million individuals were insured in U.S.

Various strategic initiatives such as partnerships, collaborations, mergers and acquisitions are likely to boost the urgent care market. For instance, in June 2018, CityMD acquired STAT Health to expand its services to 100 locations in New York City. This acquisition is expected to help address healthcare challenges and provide coordinated care.

Hospitals are increasing their interest in UC centers to maintain the balance between emergency and primary care in hospitals. UC centers now possess tools for diagnosis, blood testing, screening, radiology. Companies and the U.S. government, in collaboration with UC centers, organize certain wellness programs for improvement of health status of the nation’s population. Introduction of telemedicine is assisting these centers and enabling comfortable consultation for acute conditions.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/us-urgent-care-market

Further key findings from the report suggest:

• In U.S., injury is one of the major causes of death among children and is subsequently anticipated to increase demand for urgent care. According to the Centers for Disease Control and Prevention (CDC), in 2016, about 32,074,270 injuries were reported in the country
• By application, acute respiratory infection accounted for the largest share in the market in 2017 due to treatment at low cost for infections such as asthma, bronchitis, cough, nausea, and sore throat
• The hospital-owned segment, supported by joint ventures with hospitals, accounted for the largest share in the market and is anticipated to maintain its dominance over the forecast period due to easy follow-up with specialists and physicians
• Some of the key players are Concentra, Inc.; Urgent Care MSO, LLC; American Family Care; CareNow; City Practice Group of New York; CareSpot; Fast Pace Urgent Care; Centra Care; Physicians Immediate Care; Intermountain Healthcare; Aurora Health Care; Urgent Team; Prohealth; MD Now; Hometown Urgent Care; NextCare Holdings, Inc.; and MedSpring.

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

North America Breast Reconstruction Market Worth $486.6 Million By 2025

The North America Breast Reconstruction Market size is anticipated to reach USD 486.6 million by 2025 at a 4.5% CAGR during the forecast period, according to a new report by Grand View Research, Inc. This growth can be attributed to increased awareness about physical appearance, particularly among women.

Breast reconstruction is considered to be one of the top 5 cosmetic surgical procedures in U.S. since 2006. According to estimates, there has been a 39.0% increase in this procedure since 2000 and a 3.0% rise since 2015. Thus, with rising number of reconstruction procedures being performed, demand for associated products such as implants and tissue expanders has also increased.

According to the Agency for Healthcare Research and Quality, the number of women undergoing mastectomy procedures has increased by 36.0% during the period of 2005to 2013. Increasing prevalence of breast cancer, high mortality rate associated with it, and growing number of mastectomies being performed as a result are some of the factors anticipated to drive demand for implants and tissue expanders.

Furthermore, availability of advanced technologies in this field has supported market growth. For instance, single-stage breast reconstruction has evolved as an innovative technique that combines tissue expanders and implants into a single product.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/north-america-breast-reconstruction-market

Further key findings from the study suggest:

• By product, tissue expanders held the largest market share in 2017 and the segment is anticipated to exhibit significant growth over the forecast period due to their high application in mastectomy and lumpectomy surgeries
• Breast implants generated significant revenue in 2017 owing to significant concern among people to improve or alter their physical appearances
• Round shaped implants dominated the market in 2017. These result in soft, round, and accurately proportioned breasts and eliminate any risk arising from implant rotation
• Round shaped expanders are also expected to witness lucrative growth over the forecast period due to their ability to minimize visibility of implant ripples through the skin
• Anatomical shaped products are expected to show significant CAGR over the forecast period as they present lower risk of capsular contracture as compared to smooth implants and also give a natural-looking appearance
• U.S. dominated the regional market in 2017 due to increase in number of breast reconstruction surgeries in the country
• Canada is anticipated to show significant growth over the forecast period due to rising prevalence of breast cancer among the Canadian population
• Some of the major manufacturers are Mentor Worldwide LLC; Sientra, Inc.; IDEAL IMPLANT INCORPORATED; and Allergan.

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com